2017
Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer
Shrestha B, Sun Y, Faisal F, Kim V, Soares K, Blair A, Herman JM, Narang A, Dholakia AS, Rosati L, Hacker‐Prietz A, Chen L, Laheru DA, De Jesus‐Acosta A, Le DT, Donehower R, Azad N, Diaz LA, Murphy A, Lee V, Fishman EK, Hruban RH, Liang T, Cameron JL, Makary M, Weiss MJ, Ahuja N, He J, Wolfgang CL, Huang C, Zheng L. Long‐term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. Cancer Medicine 2017, 6: 1552-1562. PMID: 28639410, PMCID: PMC5504321, DOI: 10.1002/cam4.1104.Peer-Reviewed Original ResearchConceptsMedian overall survivalUpfront chemotherapyNeoadjuvant chemotherapyNeoadjuvant therapySurgical resectionOverall survivalUpfront chemoradiationBorderline resectable pancreatic adenocarcinomaLong-term survival benefitBorderline resectable pancreatic cancerCurative surgical resectionResectable pancreatic cancerUpfront neoadjuvant chemotherapyResectable pancreatic adenocarcinomaSubpopulation of patientsJohns Hopkins HospitalLong-term survivalCurative intentNeoadjuvant chemoradiationConsecutive patientsSurvival benefitPancreatic cancerPancreatic adenocarcinomaRetrospective analysisChemoradiation
2015
Multimodal Therapy in the Treatment of Prostate Sarcoma: The Johns Hopkins Experience
Ball MW, Sundi D, Reese AC, Meyer CF, Terezakis SA, Efron JE, Schoenberg MP, Epstein JI, Ahuja N, Bivalacqua TJ. Multimodal Therapy in the Treatment of Prostate Sarcoma: The Johns Hopkins Experience. Clinical Genitourinary Cancer 2015, 13: 435-440. PMID: 26003268, DOI: 10.1016/j.clgc.2015.04.011.Peer-Reviewed Original ResearchConceptsCancer-specific survivalRecurrence-free survivalProstate sarcomaOverall survivalSurgical resectionLocal recurrenceMedian recurrence-free survivalFavorable cancer-specific survivalCommon presenting symptomRecords of patientsPatient demographic informationJohns Hopkins ExperienceActuarial OSConcurrent chemotherapyCurative intentMedian OSNeoadjuvant chemoradiationNeoadjuvant radiationOncological outcomesPresenting symptomMost patientsRFS ratesUrinary obstructionMetastatic recurrenceTumor characteristics
2011
Neoadjuvant chemoradiation followed by interstitial prostate brachytherapy for synchronous prostate and rectal cancer
Qiu H, Herman JM, Ahuja N, DeWeese TL, Song DY. Neoadjuvant chemoradiation followed by interstitial prostate brachytherapy for synchronous prostate and rectal cancer. Practical Radiation Oncology 2011, 2: e77-e84. PMID: 24674189, DOI: 10.1016/j.prro.2011.11.001.Peer-Reviewed Original ResearchSynchronous prostateRectal cancerAdjuvant chemotherapyPelvic chemoradiationProstate brachytherapyGrade 3 gastrointestinal toxicityHigh-risk prostate cancerCarcinoembryonic antigen levelLow anterior resectionTreatment-related toxicityEvidence of relapseInterstitial prostate brachytherapyProstate interstitial brachytherapyInternal Review BoardAnterior resectionBony metastasesGastrointestinal toxicityLoop ileostomyNeoadjuvant chemoradiationRetrospective reviewAntigen levelsMonths postdiagnosisPhysical examinationProstate cancerInterstitial brachytherapy